Cidara Therapeutics Inc share price logo

Cidara Therapeutics Inc Share Price

NASDAQ: CDTX

$221.38

+0.06

(+0.03%)

as on

Bell Icon

The stock has been delisted from the stock exchange on 6 Jan 2026

Cidara Therapeutics Inc Stock Performance

as on January 7, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $221.25
    $221.41
    downward going graph

    0.06%

    Downside

    0.01%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $15.22
    $221.42
    downward going graph

    93.12%

    Downside

    0.02%

    Upside

    downward going graph

Cidara Therapeutics Inc share price movements today

Previous Close
$221.32
Open
$221.35
Volume
1.1M
Day's Low - High
$221.25 - $221.41
52 Week Low - High
$15.22 - $221.42

Cidara Therapeutics Inc Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Cidara Therapeutics Inc Stock Fundamentals & Key Indicators

Check Cidara Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

Cidara Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cidara Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Cidara Therapeutics Inc image
Cidara Therapeutics Inc
BUY$-NANA0.00%
Insmed Incorporated image
Insmed Incorporated
BUY$31.7B315.46%-16.34-210.54%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$44.1B121.04%142.858.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$123.8B127.26%31.8432.94%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$81.6B74.06%18.6231.41%

Analyst Recommendation on Cidara Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Cidara Therapeutics Inc. Average target price of $221.5

Cidara Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Cidara Therapeutics Inc.

What analysts predicted

0.05%UPSIDE

Target Price

$221.5

Current Price

$221.38

Analyzed by

10 Analysts

Target

$221.50

Cidara Therapeutics Inc target price $221.5, a slight upside of 0.05% compared to current price of $221.38. According to 10 analysts rating.

Cidara Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
5
9
17
0
0
-
-
-
-
-
Gross Profit
5
-1
16
-4
0
0
-90
0
0
-45
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-13
-9
-5
-10
-91
-15
-52
-23
-25
-83
Net Profit Margin
-267.66%
-98.81%
-31.91%
-1061.25%
-30201.66%
0.00%
0.00%
0.00%
0.00%
0.00%

Cidara Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
20
12
49
64
23
1
Gross Profit
0
0
-42
0
-25
12
49
64
-13
1
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-32
-48
-55
-59
-41
-72
-43
-29
-22
-169
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-196.47%
-597.59%
-88.58%
-46.35%
-98.49%
-13319.76%

Global Institutional Holdings in Cidara Therapeutics Inc

Funds
Holdings
VR Adviser, LLC
2.52%
Ikarian Capital, LLC
1.83%
Jefferies Financial Group Inc
1.77%
Citadel Advisors Llc
1.15%
Bain Capital Life Sciences Investors, LLC
9.86%
See all

Cidara Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 17 November

    Mon, 08:46 PM

    -

    Merck announces $9.2 billion acquisition of Cidara, expecting significant commercial opportunity from its flu drug.

    Mon, 09:07 PM

    -

    TCG Crossover Management sells $49 million stake in Cidara, missing out on significant gains from Merck's acquisition announcement.

Insights on Cidara Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CDTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CDTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, CDTX stock has moved up by 334.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -23.48M → -83.23M (in $), with an average decrease of 116.6% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 17.58M → 302.0K (in $), with an average decrease of 81.7% per quarter

About Cidara Therapeutics Inc

Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
OrganisationCidara Therapeutics Inc
E-voting on sharesClick here to vote

FAQs

What is Cidara Therapeutics Inc share price today?

Cidara Therapeutics Inc share price today is $221.38 as on at the close of the market. Cidara Therapeutics Inc share today touched a day high of $221.41 and a low of $221.25.

What is the 52 week high and 52 week low for Cidara Therapeutics Inc share?

Cidara Therapeutics Inc share touched a 52 week high of $221.42 on and a 52 week low of $15.22 on . Cidara Therapeutics Inc stock price today i.e. is closed at $221.38,which is 0.02% down from its 52 week high and 1354.53% up from its 52 week low.

How to invest in Cidara Therapeutics Inc Stock (CDTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cidara Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cidara Therapeutics Inc Shares that will get you 0.0068 shares as per Cidara Therapeutics Inc share price of $221.38 per share as on January 7, 2026 at 2:29 am IST.

What is the minimum amount required to buy Cidara Therapeutics Inc Stock (CDTX) from India?

Indian investors can start investing in Cidara Therapeutics Inc (CDTX) shares with as little as ₹90.899 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹908.99 in Cidara Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Cidara Therapeutics Inc share’s latest price of $221.38 as on January 7, 2026 at 2:29 am IST, you will get 0.0452 shares of Cidara Therapeutics Inc. Learn more about fractional shares .